Compare Abeona Therapeutics Inc (ABEO) vs Remitly Global Inc (RELY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Remitly Global Inc — how do they compare? Abeona Therapeutics Inc trades at $6.62 (market cap $373.32M), while Remitly Global Inc trades at $23.38 (market cap $5.08B). The key difference: Remitly Global Inc is far larger — about 13.6× Abeona Therapeutics Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | RELY | |
|---|---|---|
Market Cap | $373.32M | $5.08B |
Sector | Health | Technology |
52-Week High | $7.23 | $24.28 |
52-Week Low | $4.17 | $12.20 |
Enterprise Value | $228.22M | $4.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
RELY trades at $24.13, up 1.6% on the day, with strong bullish technical signals from moving averages and a consensus analyst price target of $25.67. The company shows accelerating revenue growth, reaching $1.64 billion in 2025, and has achieved profitability with net income of $67.93 million. Recent news highlights expansion into Canada and new business features driving investor optimism.
Outlook remains positive due to sustained revenue growth and market expansion, though high valuation multiples and overbought RSI levels pose near-term risks. The stock offers growth potential in digital payments but faces execution and competitive pressures in the remittance space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
